The urokinase receptor. Protein structure and role in plasminogen activation and cancer invasion

Fibrinolysis and Proteolysis

Volumn 8, Issue SUPPL. 1, 1994, Pages 189-203

  Dano K ^a   Behrendt, N ^b   Brunner, N ^b   Ellis, V ^b   Ploug, M ^b   Pyke, C ^b  

^a FINSEN LABORATORY   (Denmark)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

PLASMINOGEN ACTIVATOR; UROKINASE; UROKINASE RECEPTOR;

CANCER INVASION; CONFERENCE PAPER; HUMAN; NONHUMAN; PRIORITY JOURNAL; PROTEIN STRUCTURE; RECEPTOR BINDING;

EID: 0027994264     PISSN: 02689499     EISSN: None     Source Type: Journal    
DOI: 10.1016/0268-9499(94)90717-X     Document Type: Article

References (159)

1. CHARACTERISTICS OF GROWTH OF SARCOMA AND CARCINOMA CULTIVATED IN VITRO
2. CULTIVATION IN VITRO OF MALIGNANT TUMORS
3. Mechanism of the proteolysic activity of malignant tissue cells
4. Experimental Alteration of the Ability of Tumor Cells to Lyse Plasma Clots in vitro
5. An enzymatic function associated with transformation of fibroblasts by oncogenic viruses. I. Chick embryo fibroblast cultures transformed by avian RNA tumor viruses
6. AN ENZYMATIC FUNCTION ASSOCIATED WITH TRANSFORMATION OF FIBROBLASTS BY ONCOGENIC VIRUSES: II. MAMMALIAN FIBROBLAST CULTURES TRANSFORMED BY DNA AND RNA TUMOR VIRUSES
7. Fibrinolysis associated with oncogenic transformation: Partial purification and characterization of the cell factor—a plasminogen activator
8. Plasminogen, a necessary factor for cell migration in vitro
9. The Primary Structure of High Molecular Mass Urokinase from Human Urine. The Complete Amino Arid Sequence of the A Chain
10. + RNA
11. Purification and characterization of a melanoma cell plasminogen activator
12. Isolation of cDNA sequences coding for a part of human tissue plasminogen activator
13. Cloning and expression of human tissue-type plasminogen activator cDNA in E. coli
14. Activation of plasminogen: a general mechanism for producing localized extracellular proteolysis
15. Plasminogen activators tissue degradation and cancer
16. Urokinase-type plasminogen activator: proenzyme, receptor, and inhibitors
17. Cell-associated plasminogen activation: Regulation and physiological functions
18. The plasminogen activator/plasmin system
19. Directed plasminogen activation at the surface of normal and malignant cells
20. The receptor for urokinase plasminogen activator. Stromal cell involvement in extracellular proteolysis during cancer invasion
21. Plasminogen activator released as inactive proenzyme from sarcoma virus transformed murine cells
22. Purification of zymogen to plasminogen activator from human glioblastoma cells by affinity chromatography with monoclonal antibody
23. Plasminogen activation by receptor-bound urokinase
24. Potentiation of plasminogen activation by an anti-urokinase monoclonal antibody due to ternary complex formation: a mechanistic model for receptor-mediated plasminogen activation
25. A cellular binding site for the Mr 55,000 form of the human plasminoigen activator, urokinase
26. Differentiation-enhanced binding of the aminoterminal fragment of human urokinase plasminogen activator to a specific receptor on U937 monocytes
27. The plasminogen system and cell surfaces: Evidence for plasminogen and urokinase receptors on the same cell type
28. A 55,000–60,000 Mr receptor protein for urokinasetype plasminogen activator. Identification in human tumor cell lines and partial purification
29. Characterization of the cellular binding site for the urokinase-type plasminogen activator
30. The human receptor for urokinase plasminoigen activator. N-terminal amino acid sequence and glycosylation variants
31. Characterization of human endothelial cell urokinase-type plasminogen activator receptor protein and messenger RNA
32. Identification and characterization of the murine cell surface receptor for the urokinase type plasminogen activator
33. The urokinase receptor: structure, regulation and inhibitor-mediated internalization
34. Two alternatively spliced mouse urokinase receptor mRNAs with different histological localization in the gastrointestinal tract
35. Bovine urokinase-type plasminogen activator and its receptor: cloning and induction by retinoic acid
36. Isolation and characterization of multiple isoforms of the rat urokianse receptor in osteoblasts
37. Assignment of the urokinase-type plasminogen activator receptor gene (PLAUR) to chromosome 19q13.1-q13.2.
38. Plasminogen activation initiated by single-chain urokinase-type plasminogen activator. Potentiation by U937 monocytes
39. Activation of prourokinase and plasminogen on human sarcoma cells: A proteolytic system with surface-bound reactants
40. Cell-induced potentiation of the plasminogen activation system is abolished by a monoclonal antibody that recognizes the NH2-terminal domain of the urokinase receptor
41. Plasminogen activator inhibitors: hormonally regulated serpins
42. Inhibition of receptor-bound urokinase by plasminogen-activator inhibitors
43. Accessibility of receptor-bound urokinase to type-1 plasminogen activator inhibitor
44. Receptor-mediated internalization and degradation of urokinase is caused by its specific inhibitor PAI-1
45. 2-macroglobulin receptor mediates cellular degradation of urokinase receptor bound complexes
46. Urokinase-type plasminogen activator is expressed in stromal cells and its receptor in cancer cells at invasive foci in human colon adenocarcinomas
47. The receptor for urokinase is present in tumor-associated macrophages in ductal breast carcinoma
48. Immunohistochemical detection of the receptor for urokinase plasminogen activator in human colon cancer
49. Histological investigation of human metastasizing tumors for components of the plasminogen activation system
50. The ligand-binding domain of the cell surface receptor for urokinase-type plasminogen activator
51. Cellular receptor for urokinase-type plasminogen activator: protein structure
52. Localization of the disulfide bonds in the NH2terminal domain of the cellular receptor for human urokinasetype plasminogen activator. A domain structure belonging to a novel superfamily of glycolipid anchored membrane proteins
53. Ligand interaction between urokinase-type plasminogen activator and its receptor probed with 8-anilino-I-naphthalene sulfonate. Evidence for a hydrophobic binding site exposed only on theintact receptor
54. A soluble, ligand binding mutant of the human urokianse plasminogen activator receptor
55. Quantitation of the receptor for urokinase plasminogen activator by enzyme-linked immunosorbent assay
56. Cloning and expression of the receptor for human urokinase-plasminogen activator, a central molecule in cell-surface plasmin-dependent proteolysis
57. N-linked glycosylation of the ligand-binding domain of the human urokinase receptor contributes to the affinity for its ligand.
58. Regulation of urokinase receptors in monocytelike U937 cells by phorbol ester phorbol pyristate acetate
59. Cellular receptor for urokinase plasminogen activator: carboxyl-terminal processing and membrane anchoring by glycosyl-phosphatidylinositol
60. Structural requirements for glycosyl-phosphatidylinositol-anchor attachment in the cellular receptor for urokinase plasminogen activator
61. The urokinase-type plasminogen activator receptor is a member of the Ly-6 superfamily
62. Herpesvirus saimiri has a gene specifying a homologue of the cellular membrane glycoprotein CD59
63. Urokinase plasminogen activator cleaves its cell surface receptor releasing the ligand-binding domain.
64. Determination of carboxyl-terminal residue and disulfide bonds of MACIF (CD59), a glycosyl phosphatidylinositol anchored membrane protein
65. Structure-function relationships in the receptor for urokinase-type plasminogen activator. Comparison to other members of the Ly-6 family and snake venom a neurotoxins
66. Structure of the snake short-chain neurotoxin, erabutoxin c, precursor gene
67. Three-dimensional solution structure of the extracellular region of the complement regulatory protein CD-59, a new cell-surface protein domain related to snake venom neurotoxins
68. Structure of a soluble, glycosylated form of the human complement reglatory protein CD-59
69. An alternative Ly spliced variant of mRNA for the human receptor for urokinase plasminogen activator
70. Ultrastructural localization of plasma membrane-associated urokinase- type plasminogen activator at focal contacts
71. Linkage of extracellular plasminogen activator to the fibroblast cytoskeleton: colocalization of cell surface urokinase with vinculin
72. Distribution and lateral mobility of the urokinase-receptor complex at the cell surface.
73. Heparin binding to the urokinase kringle domain.
74. A novel, specific pro-urokinase complex on monocyte-like cells, detected by transglutaminasecatalyzed cross-linking
75. Plasminogen activation by receptor-bound urokinase: A kinetic study with both cellassociated and isolated receptor
76. The cellular receptor for urokinase-type plasminogen activator: function in cell-surface proteolysis
77. Role of cell-surface lysines in plasminogen binding to cells: Identification of α-enolase as a candidate plasminogen receptor
78. Molecular cloning of an endothelial cell tissue plasminogen activator/plasminogen receptor: Annexin II-related protein
79. Gangliosides interact directly with plasminogen and urokinase and may mediate binding of these
80. Plasminogen activation by single-chain urokinase in functional isolation
81. Expression of an anchored urokinase in the apical endothelial cell membrane
82. Characterization of plasminogen activation by glycosylphosphatidylinositol-anchored urokinase.
83. 2-macroglobulin
84. Signal transducing molecules and glycosyl-phosphateidylinositollinked proteins form a caveolin-rich insoluble complex on MDCK cells
85. Interaction of urokinasetype plasminogen activator (uPA) with its cellular receptor (uPAR) induces phosphorylation on tyrosine of a 38 kDa protein
86. Proliferation of a human epidermal tumor cell line stimulated by urokinase
87. Growth factor-like effect of urokinase type plasminogen activator in human renal cells
88. The extracellular regulation of growth factor action
89. Extracellular proteolytic cleavage by urokinase is required for activation of hepatocyte growth factor/scatter factor
90. Structural requirements for the growth factor activity of the amino-terminal domain of urokinase
91. Urokinase-urokinase receptor interaction: Non-mitogenic signal transduction in human epidermal cells
92. The urokinase receptor is required for human monocyte chemotaxis in vitro
93. The receptor for urokinase type plasminogen activator polarizes expression of the protease to the leading edge of migrating monocytes and promotes degradation of enzyme inhibitor complexes
94. Urokinase receptors in human monocytes
95. Localization of urokinase-type plasminogen activator in stromal cells in adenocarcinomas of the colon in humans.
96. Location of plasminogen activator (PA) and PA inhibitor in human colorectal adenocarcinomas
97. Plasminogen activators and plasminogen activator inhibitors in human colorectal carcinoima tissues are not expressed by the tumour cells
98. Messenger RNA for plasminogen activator inhibitor type-1 is present in endothelial cells in malignant colorectal tumors in man
99. Plasminogen activator inhibitor from human fibrosarcoma cells binds urokinase-type plasminogen activator, but not its proenzyme
100. Plasminogen activator inhibitor type I in Lewis lung carcinoma
101. Distribution of collagenase and tissue inhibitor of metal loproteinases (TIMP) in colorectal tumours
102. Stromal expression of 72 kda type IV collagenase (MMP-2) and TIMP-2 mRNAs in colorectal neoplasia
103. Messenger RNA for two type IV collagenases is located in stromal cells in human colon cancer
104. The matrix metal loproteinase pump-1 catalyzes formation of low molecular weight (pro)urokinase in cultures of normal human kidney cells
105. Expression and localization of the matrix metal loproteinase pump- I (MMP-7) in human gastric and colon carcinomas
106. The urokinase receptor is expressed in invasive breast cancer but not in normal breast tissue
107. Expression of the stromelysin-3 gene in fibroblastic cells of invasive carcinomas of the breast and other human tissues: a review
108. Type- I plasminogen activator inhibitor in human breast carcinomas
109. A new member of the metal loproteinase gene family is specifically expressed in stromal but not in tumor cells of breast carcinomas
110. Stromelysin 3 belongs to a subgroup of proteinases expressed in breast carcinoma fibroblastic cells and possibly implicated in tumor progression
111. Expression of gelatinase A and TIMP-2 mRNAs in desmoplastic fibroblasts in both mammary carcinomas and basal cell carcinoimas of the skin
112. Activity of type IV collagenases in benign and malignant breast disease
113. Detection and localization of mRNAs encoding matrix metal loproteinases and their tissue inhibitor in human breast pathology
114. Differential protease expression by cutaneous squamous and basal cell carcinomas
115. Localization of messenger RNA for M, 72,000 and 92,000 type IV collagenases in human skin cancers by in situ hybridization
116. Localization by in situ hybridization of mRNAs encoding stromelysin 3 and tissue inhibitors of metal loproteinases TIMP- I and TIMP-2 in human head and neck carcinomas
117. Increased stromelysin 3 gene expression is associated with increased local invasiveness in head and neck squamous cell carcinomas
118. Plasminogen activators, their inhibitors, and urokinase receptor emerge in late stages of melanocytic tumor progression
119. The receptor for urokinase-type plasminogen activator and urokinase is translocated from two distinct intracellular compartments to the plasma membrane on stimulation of human neutrophils
120. Human neutrophil plasminogen activator is located in specific grandules and is translocated to the cell surface by exocytosis
121. The receptor for urokinase-type plasminogen activator is deficient on peripheral blood leukocytes in patients with paroxysmal nocturnal hemoglobinuria
122. Distribution of urokinase-type plasminogen activator immunoreactivity in the mouse
123. Localization of urokinae-type plasminogen activator messenger RNA in the normal mouse by in situ hybridization
124. The Receptor for Urokinase-type Plasminogen Activator is Expressed by Keratinocytes at the Leading Edge During Re-Epithelialization of Mouse Skin Wounds.
125. Urokinase- and Tissue-Type Plasminogen Activators in Keratinocytes During Wound Reepithelialization In Vivo.
126. Differential Expression of Urokinase-Type Plasminogen Activator and Its Type-1 Inhibitor During Healing of Mouse Skin Wounds.
127. Urokinase receptor mRNA level and gene transcription are strongly and rapidly increased by phorbol myristate acetatein human monocyte-like U937 cells
128. Urokinase receptor biosynthesis, mRNA level and gene transcription are increased by transforming growth factor-β1 in human A549 lung carcinoma cells
129. lacZ transduced human breast cancer xenografts as an in vivo model for the study of invasion and metastasis
130. Expression of uPA and its receptor by both neoplastic and stromal cells during xenograft invasion
131. The urokinase receptor: involvement in cell surface proteolysis and cancer invasion
132. Breast-cancer-associated stromelysin-3 gene is expressed in basal cell carcinoma and during cutaneous wound healing
133. Tumors: Wounds That Do Not Heal
134. Antibodies to plasminogen activator inhibit human tumor metastasis
135. Inhibition of urokinase-type plasminogen activator by antibodies: The effect on dissemination of a human tumor in the nude mouse
136. Plasminogen activator dependent pathways in the dissemination of human tumor cells in the chick embryo
137. In vivo invasion of modified chorioallantoic membrane by tumor cells: the role of cell surface-bound urokinase
138. In vivo paracrine interaction between urokinase and its receptor: effect on tumor cell invasion
139. Prevention of metastasis by inhibition of the urokinase receptor
140. Binding of the urokinase-type plasminogen activator to the cell surface receptor is inhibited by low doses of suramin
141. Specific inhibition of the activity of the urokinase receptor-mediated cell surface plasminogen activation system by suramin
142. Paroxysmal nocturnal hemoglobinuria: Clinical manifestations, haematology, and nature of the disease
143. Experimentally developed cellular resistance to Daunomycin. Mechanisms of resistance, the Daunomycinpump and cross resistance to Adriamycin, Vincristine and Vinblastine
144. Physioloigical consequences of loss of plasminogen activator gene function in mice
145. Urokinase-plasminogen activator, a new and independent prognostic marker in breast cancer
146. Clinical Relevance of the Urokinase-Type and Tissue-Type Plasminogen Activators and of Their Type 1 Inhibitor in Breast Cancer
147. Prognostic value of urokinase-type plasminogen activator in 671 primary breast cancer patients
148. High levels of urokinase-type plasminogen activator and its inhibitor PAI-1 in cytosolic extracts of breast carcinomas are associated with poor prognosis.
149. A ligand-free, soluble urokinase-receptor is present in the ascites fluid from patients with ovarian cancer
150. Urokinase and plasminogen activator inhibitor type 1 in pulmonary adenocarcioma
151. Conformational properties of the neurotoxins and cytotoxins isolated from Elapid snake venoms